期刊
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
卷 10, 期 5, 页码 649-658出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474124.2016.1139450
关键词
HBV infection; antiviral therapy; interferon; entecavir; children
Chronic hepatitis B (CHB) in children shows a variety of clinical presentations, which influence its natural course and treatment options. This report provides an overview of the ongoing strategies in pediatric CHB management. Interferon- represents the first choice of treatment in children showing HBV replication and hepatic inflammation (immune active CHB), while the recommendation is to monitor inactive/immune-tolerant children (normal transaminases and low/absent viral replication). When circumstances preclude the use of Interferon- and in cases of compensated/decompensated cirrhosis, entecavir for children above 2 years of age or tenofovir for children above 12 years of age are the nucleos(t)ide analogues recommended by the most recent guidelines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据